GART
ENSG00000159131
Target class
Enzyme
Chromosome
21
Approved drugs
5
Clinical candidates (approved and in development)
6
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- Yes
- Other names
- GARS-AIRS-GART
- Target name
- GART
- Gene name
- Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase
- Gene symbol
- GART
- Protein name
- Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase (EC 6.3.4.13) (Glycinamide ribonucleotide synthetase) (GARS) (Phosphoribosylglycinamide synthetase); Phosphoribosylformylglycinamidine cyclo-ligase (EC 6.3.3.1) (AIR synthase) (AIRS) (Phosphoribosyl-aminoimidazole synthetase); Phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) (5'-phosphoribosylglycinamide transformylase) (GAR transformylase) (GART)]
- PRGS
- PGFT
- Gene biotype
- Protein coding
- Gene family
- Purinosome|ATP-grasp fold containing
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 64.02
- Tissue specificity (Gini)
- 0.284
- Tissue specificity (tau)
- 0.729
- KEGG gene identifiers
- hsa:2618
- Reactome pathways
- R-HSA-73817
- Protein interaction confidence
- 0.858988
- Protein interaction partners
- 84
- End position
- 33543524
- Start position
- 33503371
- Chromosome
- 21
- Strand
- Reverse
- Cytosol
- Mitochondria
- Tissue specificity (tau)
- 0.728917
- Expression inequality (Gini)
- 0.283854
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 64.02
- Cells - EBV-transformed lymphocytes
- 60.29
- Testis
- 33.73
- Adipose - Subcutaneous
- 25.75
- Adipose - Visceral (Omentum)
- 25.14
Expression in transcripts per million
- Cells - Cultured fibroblasts64.02
- Cells - EBV-transformed lymphocytes60.29
- Testis33.73
- Adipose - Subcutaneous25.75
- Adipose - Visceral (Omentum)25.14
- Breast - Mammary Tissue24.72
- Nerve - Tibial24.35
- Esophagus - Mucosa24.32
- Uterus24.11
- Bladder23.83
- Ovary23.42
- Fallopian Tube22.52
- Cervix - Ectocervix22.51
- Artery - Coronary22.29
- Vagina22.03
- Artery - Tibial21.84
- Thyroid21.49
- Spleen21.47
- Lung21.26
- Artery - Aorta21.18
- Cervix - Endocervix20.86
- Colon - Sigmoid19.6
- Esophagus - Muscularis19.45
- Skin - Sun Exposed (Lower leg)19.33
- Small Intestine - Terminal Ileum18.88
And 29 more, listed on the interactive page.
- GO:0006177
- GO:0006189
- GO:0009168
- GO:0044208
- GO:0097294
- GO:0005829
- GO:0070062
- GO:0004637
- GO:0004641
- GO:0004644
Related records
Trials (1,073)
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
- A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors
- A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer
- A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
- A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
- A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
- A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
- A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
- A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
- A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
- A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
- A Phase 1 Study in Patients With Solid Tumors
Drugs (6)
- Pelitrexol GAR transformylase inhibitor
- Pemetrexed GAR transformylase inhibitor
- Pemetrexed dipotassium GAR transformylase inhibitor
- Pemetrexed disodium GAR transformylase inhibitor
- Pemetrexed monohydrate GAR transformylase inhibitor
- Pemetrexed tromethamine GAR transformylase inhibitor